Show simple item record

dc.contributor.authorRodrigues, Michelle
dc.contributor.authorPandya, Amit G.
dc.contributor.authorHamzavi, Iltefat
dc.contributor.authorEzzedine, Khaled
dc.contributor.authorBekkenk, Marcel W.
dc.contributor.authorHarris, John E.
dc.date2022-08-11T08:08:10.000
dc.date.accessioned2022-08-23T15:45:02Z
dc.date.available2022-08-23T15:45:02Z
dc.date.issued2021-05-24
dc.date.submitted2021-06-14
dc.identifier.citation<p>Rodrigues M, Pandya AG, Hamzavi I, Ezzedine K, Bekkenk MW, Harris JE. Treatment recommendations for patients with vitiligo during COVID-19. Australas J Dermatol. 2021 May 24. doi: 10.1111/ajd.13610. Epub ahead of print. PMID: 34028796. <a href="https://doi.org/10.1111/ajd.13610">Link to article on publisher's site</a></p>
dc.identifier.issn0004-8380 (Linking)
dc.identifier.doi10.1111/ajd.13610
dc.identifier.pmid34028796
dc.identifier.urihttp://hdl.handle.net/20.500.14038/27447
dc.description.abstractThe World Health Organization declared a global pandemic on 12 March 2020 due to the worldwide spread of COVID-19, caused by SARS-CoV-2.1 Vitiligo is an autoimmune disease causing skin depigmentation affecting 0.5%–2% of the population. We do not project an increased risk of infection from COVID-19 in those with vitiligo, as the immune system of such individuals is not compromised and there is currently no evidence that the virus infects melanocytes. However, some patients may have treatment-related immunosuppression and some may have to access in-office narrow band ultraviolet light B (NB-UVB), which could increase their risk of developing COVID-19. At this time, there is a need to balance treatment for vitiligo with the need to reduce exposure to SARS-CoV-2. We have thus outlined the following treatment considerations to guide clinicians in the treatment of their vitiligo patients.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=34028796&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://doi.org/10.1111/ajd.13610
dc.subjectvitiligo
dc.subjectCOVID-19
dc.subjectDermatology
dc.subjectHealth Services Administration
dc.subjectInfectious Disease
dc.subjectSkin and Connective Tissue Diseases
dc.subjectTherapeutics
dc.subjectVirus Diseases
dc.titleTreatment recommendations for patients with vitiligo during COVID-19
dc.typeLetter to the Editor
dc.source.journaltitleThe Australasian journal of dermatology
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/covid19/248
dc.identifier.contextkey23348824
html.description.abstract<p>The World Health Organization declared a global pandemic on 12 March 2020 due to the worldwide spread of COVID-19, caused by SARS-CoV-2.<sup><a href="https://onlinelibrary.wiley.com/doi/10.1111/ajd.13610#ajd13610-bib-0001" id="x-x-ajd13610-bib-0001R">1</a></sup> Vitiligo is an autoimmune disease causing skin depigmentation affecting 0.5%–2% of the population. We do not project an increased risk of infection from COVID-19 in those with vitiligo, as the immune system of such individuals is not compromised and there is currently no evidence that the virus infects melanocytes. However, some patients may have treatment-related immunosuppression and some may have to access in-office narrow band ultraviolet light B (NB-UVB), which could increase their risk of developing COVID-19. At this time, there is a need to balance treatment for vitiligo with the need to reduce exposure to SARS-CoV-2. We have thus outlined the following treatment considerations to guide clinicians in the treatment of their vitiligo patients.</p>
dc.identifier.submissionpathcovid19/248
dc.contributor.departmentDepartment of Dermatology


This item appears in the following Collection(s)

Show simple item record